







FIG. 1B








FIG. 2A












FIG. 5




FIG. 6





FIG. 7






FIG. 9




FIG. 10




FIG. 11




FIG. 12

Geometric Mean Titers and 95% CI: HAI - Vaccine Preparations 5, 6 and Control Groups - Evaluable Immunogenicity Population




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 20
CONTINUED




FIG. 21




FIG. 22




FIG. 22
CONTINUED




FIG. 23




FIG. 23
CONTINUED




FIG. 24




FIG. 24
CONTINUED





FIG. 25

Day 42 (2wks PD2) B/Phuket



Day 42 (2wks PD2) B/Phuket




FIG. 25
CONTINUED




FIG. 26




FIG. 26
CONTINUED




FIG. 27




FIG. 27
CONTINUED